# Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

> **NCT04939090** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 227 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Anorexia
- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Megestrol Acetate
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04939090
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-03
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939090, "Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04939090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*